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ABSTRACT 
_________________________________________________________________________________________ 
 
Purpose: The purpose of this paper is to highlight 
a fundamental gap in the economic research on 
obesity - the demand for unnecessary weight gain 
preventive goods. Such research is important as it 
will provide understanding of people’s preventive 
behaviours and for that matter inform policies and 
practices with regards to influencing people’s 
uptake of obesity preventive goods.  
Materials and methods: Using MeSH and PICO 
approaches, a search strategy was developed to 
search for relevant articles in a number of 
academic and scientific journal repositories 
including PubMed Central, EconLit, Medline, 
Medscape and relevant (economic) journals’ 
archives. The search strategy combined 
terms/phrases to look for publications.  
Results: A total of 1351 potentially relevant 
articles (titles and abstracts) were reviewed. No 
publications could be found that concerned 
people’s preventive behaviours in terms of demand 
with respect to obesity preventive goods. Only one 
article which was not specific to obesity looked 
into people’s preventive behaviours using an 
economic model. 
Conclusions: Despite the huge economic and 
health burden of obesity, participations in activities 
deemed supportive to weight gain prevention are 
dismal. It must not therefore be assumed that there 
will be demand for all effective weight preventive 
goods/services. As a result of the complex nature 
of the condition, the demand for obesity preventive 
goods requires understanding of the complex 
factors which influence individual decisions. The 
behavioural economic perspective could help to 
increase understanding of the preferences of 
people as it examines how decisions are made by 
individuals in complex socio-economic and socio-
cultural circumstances and financial constraints 
involving trade-offs.  
Key words: Obesity, overweight, demand, 
economics, prevention, preventive goods. 
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INTRODUCTION 
 
 Overweight and Obesity, defined by the 
World Health Organisation as “abnormal or 
excessive fat accumulation that presents a risk to 
health [1],” and widely measured as Body Mass 
Index (BMI) of 25-29.9 for overweight and ≥30 
for obese, are among leading causes of preventable 
morbidity and mortality in the United Kingdom 
(UK) [2-5] and worldwide [6,7]. Being both a 
major risk factor for several chronic diseases [3, 8-
41], and a condition of its own with severe impact 
on Health Related Quality of Life (HRQoL) [11, 
38, 42-50], the health and economic implications 
of the pandemic are enormous. Estimates suggest 
that overweight/obesity and related illnesses cost 
healthcare systems around the world millions of 
pounds annually [17,25,28,32].  
 Since obesity (used from here to 
collectively refer to overweight and obesity unless 
otherwise stated) is generated by energy imbalance 
between calories consumed and expended, that 
highlights its behavioural nature. In that respect, 
the risk of obesity related morbidity and mortality 
can be reduced through preventive behaviours. To 
date, studies into the understanding of preventive 
behaviour and its determinants have been 
examined mainly from psychological and 
sociological perspectives [10,14,26,31]. Most of 
these, which were not specifically on obesity, 
centre on the Health Belief Model (HBM) [14] 
which has several limitations.  
 Preventive health behaviours refer to the 
actions to prevent the development of ill health. 
These actions involve consumption of goods which 
reduce risks of future ill health. Such goods have 
been defined as “preventive goods”[14] and 
mainly fall under economic disciplinary research. 
As a behavioural science, economics considers 
consumer behaviour in the context of utility 
theory. However, this conventional utility theory 
cannot fully explain people’s behaviours with 
regards to obesity prevention as there are many 
other factors at play. 
 Economists have paid little attention to 
why the uptake of weight reduction activities is 
low and there remains a need to gain an 
understanding of the behaviours of both the obese 
population and those of normal weight with regard 
to individuals’ demand for preventive goods. The 
aim of this paper is to search relevant publications 
which address the issue of why some people 
demand obesity preventive goods whilst others do 
not i.e. why people behave the way they do with 
regard to demanding abnormal weight gain 
preventive goods. The main objective therefore, is 
to highlight a fundamental gap in the economic 
research on obesity - the demand for unnecessary 
weight gain preventive goods.  
 This paper begins by putting the 
pandemic into context in terms of its health and 
economic impact. In highlighting the gap in 
economic research and how it should be 
approached, this work provides a synopsis of 
research initiatives thus far on the drugs 
development front. This synopsis has been 
provided because any eventual successes in 
developing effective anti-obesity drugs will still be 
subjected to evaluations not just in terms of their 
effectiveness and likely impact on scarce 
healthcare resources but most importantly for 
purposes of their possible introduction into 
healthcare and their ultimate uptake by the 
population. 
 
CONTEXT 
 The morbidity and mortality impact of 
obesity has been well documented [8,15,19,24,36, 
38,39,41]. It is a risk factor for a range of 
conditions including vitamin D and B12 
deficiencies [9, 11, 18, 40], endometrial, breast and 
colon cancers, type 2 diabetes, dyslipidemia, 
coronary heart disease, hypertension, deep vein 
thrombosis and pulmonary embolism, menstrual 
abnormalities, polycystic ovarian syndrome, 
infertility, erectile dysfunction, sleep apnoea, 
asthma, gastro-oesophageal reflux, mental 
disorder, arthritis, musculoskeletal disorders, 
depression and reduced libido [8,13,15,16,20-23, 
27,29,33, 35,36,39,42-57]. Obesity has also been 
established as a condition of its own with severe 
impact on HRQoL [20,44,58-66].  
 The above impacts have huge 
implications on healthcare resource use and 
economies as a whole around the world [25,28, 39, 
67-79]. In 2003, the annual extra medical costs of 
obesity in the United States (US) were estimated to 
be about $75 billion [80] equivalent to about 4–7% 
of its healthcare expenditure [81,82]. Some five 
years later, it was estimated to have added about 
$147 billion to the country’s healthcare costs [83].  
 In most countries other than the US, 
obesity accounts for approximately 1 - 3% of total 
healthcare expenditure [32]. The aggregated costs 
of obesity in Canada is estimated to be from $1.27 
to $11.08 billion [84]. In the UK, the Health Select 
Committee of the House of Commons suggested 
that the total annual cost of obesity could be 
around £6.6–7.4 billion [25].  
 
MATERIALS AND METHODS 
 
 PubMed Central, EconLit, Medline, 
Medscape and relevant (economic) journals were 
searched together with references cited in 
identified articles.  
 Using both Medical Subject Headings and 
PICO (Participants or Population, Intervention or 
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Exposure, Comparison and Outcome) [85] 
methods, a search strategy was developed. This 
combined the terms obesity, overweight or weight 
gain, with any of the following terms/phrases: 
‘economics‘, ‘prevention’, ‘diet’, healthy diet’, 
‘calories’, ‘preventive goods’, ‘demand’, ‘physical 
activity’, ‘preventive goods demand’, ‘cost of 
illness’, ‘healthcare costs’, ‘costs and cost 
analysis’ and ‘employer health costs’ for example 
‘obesity – physical activity’. The search was not 
restricted to any date or any specific country or 
geographical region.  
 
RESULTS 
 
 In total, 1351 potentially relevant articles 
(titles and abstracts) were reviewed. Only one 
article looked at demand for physical activity 
interventions provided by the healthcare sector in 
Östergötland County of southern Sweden [86]. 
This population based survey found that only 
about 25% of the adult population was physically 
active and that higher activity levels were 
associated with younger age groups, higher 
education levels, higher income levels, and lower 
BMI. Hughes et al’s [71] paper looked at physical 
activities facilities availability and use by older 
adults (≥65 years old). Four other articles explored 
motivations for physical activities [87-90] and 
established that long-term participants in physical 
activities do it for intrinsic purposes and not 
necessarily for prevention motives.  
 Other than Leijon et al. [86] and Hughes 
et al. [71] which only discuss participation/ 
involvement in physical activities, no publications 
could be found that concerned the main area of 
interest i.e. people’s preventive behaviours in 
terms of demand with respect to obesity preventive 
goods. Only one article [14], which was not 
specific to obesity, looked into people’s preventive 
behaviours using an economic model. The rest of 
the papers dealt with the economic burden of 
obesity pandemic or the evaluation of the various 
obesity related interventions including drug 
treatments and surgery.  
 
The economic burden 
 Much is known about the economic 
impact of obesity, its cost of treatment, and the 
economic evaluations of various intervention 
programmes. The understanding of economic 
impact and the economic rationale for 
interventions have also been well presented [91-
95]. While most of the economic studies are model 
based, others have been conducted along well 
designed trials and in real life healthcare situations.  
 Tsai et al. [96], based on their review 
inclusion criteria, identified 33 studies [36, 39, 47, 
56,63, 67,70,72,76,78,79,81,97-117] published 
between 1992 and 2008 which reported on the cost 
of overweight, the cost of obesity and on the cost 
of overweight and obesity combined using BMI as 
the standard measures. The review estimated cost 
of overweight and obesity per-person in the US to 
be about $498 and $1630 respectively. Using the 
most recent US data, Finkelstein et al. [105] 
reported that obese patients incur 46% increased 
inpatient costs, 27% more physician visits and 
outpatient costs, and 80% increased spending on 
prescription drugs compared with normal-weight 
individuals. Tarride et al’s [118] recent study in 
Ontario, Canada also found similar associations 
between obesity and “negative impact on health 
and higher health care costs for adults.”  
 Besides medical costs, there are obesity 
associated indirect costs borne by society as a 
result of, for example, work absenteeism and 
reduced productivity, early retirement and pension 
payments, decreased years of disability-free life, 
and increased premature mortality before 
retirement and the resulting inadequate human 
resources supply problems [119]. If these indirect 
costs are factored, the estimated costs would be 
even much higher.  
 
Surgery  
 Bariatric surgical procedures are 
relatively effective for long-term weight loss. 
However, these surgical procedures are invasive, 
are often associated with complications [120,121] 
and are mostly restricted to patients with morbid 
obesity conditions (i.e. with a BMI of 40 kg/m
2
 or 
higher) and those with obesity-related compli-
cations [122]. Anti-obesity drugs are also frequent 
adjuncts as they have limited long-term effects 
[60] and the weight is often regained when treat-
ment is discontinued in the absence of any 
sustained behavioural modifications.  
 As per Anderson et al’s study [123,124] 
and the review by Clegg et al. [125], surgery was 
found to be cost effective in the long-term at £11 
000 per Quality Adjusted Life Year [71,125] 
compared with nonsurgical management. The 
results of the comparisons of different types of 
surgery were however equivocal [125]. 
 
Anti-obesity drugs 
 Anti-obesity drugs can be generally 
categorised into two broad groups according to 
their mode of action [126] - those that help to 
reduce energy consumption and those that 
stimulate energy expenditure. Research into the 
development of anti-obesity drugs has been 
undertaken for decades now. However, because of 
the complex nature of obesity, the development of 
anti-obesity drugs has not been a success story as 
such. Few of the drugs have successfully entered 
the market or made it through clinical trial stages. 
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In fact, most that have entered the market have 
been withdrawn as a result of poor safety records. 
Life-threatening  safety concerns led to the  with- 
drawal of many drugs including Aminorex® in 
1968, Fenfluramine® and Dexfenfluramine® in  
1997, and Phenylpropanolamine® in 2000 [127, 
128]. Table 1 provides information on the various 
anti-obesity drugs and their status.  
  
 
 
Table 1. Anti-obesity drugs and their status. 
 
Drug Trade Name Mode of Action Status (Availability) 
European 
Union 
United States 
of America 
Orlistat Xenical  Lipase inhibitor Available Available 
Orlistat Alli (OTC) Lipase inhibitor Available Available 
Phentermine Duromine, 
Ionamin 
NA/DA releasing 
agent 
Withdrawn in 
2001 
Available 
Methamphetamine Desoxyn NA/DA releasing 
agent 
Withdrawn in 
2000 
Available 
Benzphentamine Didrex Sympathomimetic Withdrawn in 
2000 
Available 
Phendimetrazine       Bontril Sympathomimetic Withdrawn in 
2000 
Available 
Diethylpropion         
(amfepramone) 
Apisate, 
Tenuate 
Sympathomimetic Withdrawn in 
2000 
Available 
Sibutramine         Reductil, 
Meridia 
NA/5-HT re-uptake 
inhibitor     
Withdrawn in 
2010 
Withdrawn in 
2010 
Rimonabant              Acomplia CB1 antagonist   Withdrawn in 
2008 
Did not get 
approved 
Phenylpropanolamine  Accutrim, 
Dexatrim 
Sympathomimetic Withdrawn in 
2000 
Withdrawn in 
2000 
Fenfluramine            Pondimin, 
Ponderax 
5-HT releasing agent Withdrawn in 
1997 
 Withdrawn in 
1997 
d-Fenfluramine         Redux 5-HT releasing agent  Withdrawn in 
1997 
 Withdrawn in 
1997 
Aminorex Aminoxaphen, 
Aminoxafen, 
Menocil, 
Apiquel 
Unknown/NA Withdrawn in 
1968 
Withdrawn in 
1968 
Zonisamide Zonegran Anti-convulsant agent  Mainly used for 
epilepsy 
treatment 
At clinical trial 
phases (phase 
3). Use not to 
exceed 
400mg/day 
Topiramate* + Phentermine Qsiva (EU) 
Qsymia (US) 
Unknown/NA + DA 
releasing agent 
Did not get 
approval 
Approved  
Sources of data: Vetter ML, Faulconbridge LF, Webb V, Wadden TA [Nat Rev E Endocrinol, 2010 Oct. 6(10):578-588]; 
Heal DJ, Gosden J, Smith SL [Neuropharmacology, 2012 Jul. 63(1):132-146]; Powell AG, Apovian CM, Aronne LJ [Clin 
Pharmacol Ther, 2011 Jul. 90(1):40-51]; Ioannides-Demos LL, Proietto J, Tonkin AM, McNeil JJ [Drug Saf, 2006 Apr. 
29(4):277-302]; The European Medicines Agency; US Federal Drugs Administration. *Topiramate alone is marketed in 
the EU under various names for treatment of epilepsy, partial and generalised seizures 
. 
  
Currently, approval has been obtained for 
clinical use for only a few drugs mainly Orlistat 
[128-131]. Nonetheless, anti-obesity drugs 
development efforts are still continuing. There are 
currently a number of drugs in development or at  
 
trial phases including Zonisamide + Bupropion 
and Lorcaserin (APD356)  [129].  
 As a result of the limited effectiveness of 
anti-obesity drugs and the safety and cost concerns 
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of surgical interventions, we tend to rely on 
behavioural      modification     interventions      for  
sustained lifestyle changes and therefore for 
obesity prevention and management. 
 
Behaviour change interventions 
 Several weight reduction/maintenance 
interventions have been subjected to economic 
evaluations. In the UK, weight problems are 
usually managed either within the National Health 
Service primary care sector or in private sector 
clinics through advice on weight control and 
management, physical exercise, lifestyle 
modifications and diet. Specialist services such as 
very low-calorie-diets (VLCD) are also available. 
Most of the economic evaluations which assessed 
these interventions have used different 
perspectives and analysed effectiveness in terms of 
changes in the HRQoL gained from a change in 
BMI for the study participants [54,125,132-142].  
 
Obesity and HRQoL 
 Obesity’s effect on mobility (a key factor 
in the assessment of HRQoL) is overtly 
observable. Its impact on HRQoL is independent 
of any related medical conditions or risks. The 
effect of obesity on HRQoL has been evaluated 
using generic instruments as well as those specific 
to weight [20,58, 61,65,66,143-145] such as EQ-
5D and Impact of Weight on Quality Of Life 
Questionnaire (IWQOL). Studies [20,65,66,143-
145] have demonstrated that obesity significantly 
impairs HRQoL.  
 While the studies have been consistent on 
its impact on the physical HRQoL component, 
there have been mixed findings with regards to the 
psychological HRQoL component. Mhuchu et al. 
[64], Wiczinski et al. [144], van Nunen et al. [66], 
and Swallen et al. [65] found significant effect of 
overweight and obesity on physical functioning 
related HRQoL but no links with the psychological 
component. These papers advanced no reason for 
the lack of relationships between BMI and the 
psychological HRQoL. While some attribute this 
to the non-obesity-specific instruments used in the 
research [61], others suggest that it is likely to be 
related to the acceptance of the condition by the 
society[65]. Jia et al. [20] did not report on the 
psychological component but found significant 
correlation between BMI and physical HRQoL. In 
addition to its impact on the physical HRQoL, 
Kolotkin et al. [61], Fontaine et al. [58], Wille et 
al. [145], Blissmer et al. [143] and Hassan et al. 
[59] found significant relationship between obesity 
and mental/psychological HRQoL. Confounding 
variables such as age, sex and socioeconomic 
factors were included in the assessments of most of 
the studies and were found to have effects on 
obesity HRQoL outcomes. 
 Clinicians, health service managers and 
policymakers have recognised the importance of 
HRQoL measurements to inform patient 
management, programme and policy decisions. A 
number of instruments have been developed for 
the purpose of HRQoL research. However, not all 
the instruments are preference-based which is a 
requirement for their use in healthcare economic 
evaluations. The relationship between (time) 
preference and obesity is crucial because an 
individual’s intertemporal choice could be the 
ultimate cause of most behaviours that lead to 
weight related problems. Intertemporal choice is a 
decision people make between two or more goods 
which have their payoffs at different times. For 
instance, most weight reduction interventions 
require individuals to stop consuming unhealthy 
foods now and/or adopt an active lifestyle now in 
order to gain future health gains. A strong 
preference for immediate enjoyment gained from 
unhealthy foods and/or sedentary lifestyle over 
future health benefits could influence people’s 
susceptibility to abnormal weight gain. 
  
DISCUSSIONS  
 
 There have been many studies into the 
understanding of the nature of obesity in terms of 
its causes, psychological effects, health impact and 
risk factors, economic impact and the evaluation 
(both economic and clinical) of its various 
interventions. Significant advancements have also 
been made in the fight against the condition. 
Among the significant strides are the surgical 
treatments [122,125,132,134,146] and the 
knowledge that adipose tissues are endocrine 
organs [147-149] i.e. they produce hormones. It is 
hence hoped that these biomedical advancements 
will sooner or later lead to a discovery of drugs 
that can permanently manipulate our genes or 
hormones to prevent the development of 
unnecessary weight.  
 Despite important advances in the 
medical, public health, and drugs developments 
and the efforts to develop lasting and more 
effective solutions, an important question remains 
unexplored in economic research. Considering the 
economic, cultural, environmental, psychological 
and the health complexities of the condition, even 
when an effective solution has been found the 
fundamental question will be whether there will be 
demand for it. There are many intervention 
programmes being undertaken around the world 
[34] at private and public sector levels as well as 
efforts through international collaborations [34, 
150-152] geared towards ameliorating the 
epidemic. However, uptake of these programmes 
remains low and they do not have lasting effects – 
a testimony to the challenges faced by public 
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health practitioners in securing adherence to 
obesity prevention guidelines.  
 In most cases, pharmaceutical firms use 
modelling to assess the possible demand and 
affordability in the pricing mechanisms of their 
products and its eventual introduction into the 
healthcare [153]. Such models primarily consider 
the effectiveness of the product, the incidence/ 
prevalence of the concerned disease, the target 
population (including their socio-economic 
characteristics) and the alternative options 
available [153]. However, obesity is incredibly 
complex and many additional variables will have 
to come to play in considering matters of demand 
for its preventive goods.  
 There is much focus by healthcare policy 
makers on the provision of supportive 
environments for individuals to help them make 
healthier choices. In the UK, the government 
seems to concentrate on providing public health 
messages promoting the consumption of 
recommended daily fruits/vegetables and food 
labelling[5, 12, 30, 37, 51]. Even though these 
public health approaches are important in any 
policy approach in controlling the pandemic, 
another fundamental area that the UK’s 
regional/devolved governments need to give 
priority to, is an understanding of the drivers that 
make some people have higher demand for 
preventive goods than others. To what extent is 
their demand affected by budget constraints, to 
what extent are they utility maximisers and what 
other variables are also at play? These issues are 
underexplored in economic research. 
 Conventional economics uses utility and 
intertemporal choice theories in the analyses of 
consumer behaviours particularly when it involves 
choices between goods whose payoffs arise at 
different points in time. Discounted Utility Model 
is the most widely used tool for the analysis which 
has several limitations including issues of 
rationality and hyperbolic discounting. Besides 
these limitations, utility theories cannot fully 
explain people’s behaviours with regards to 
obesity preventive goods. Utility is generally 
described as the satisfaction (enjoyment) gained 
from the consumption of a good/service, but the 
utility gained from the consumption of obesity 
preventive goods may not necessarily be 
instantaneous. In some situations people get no 
immediate enjoyment from consuming obesity 
preventive goods with all benefits occurring in the 
future. In these cases demand can be said to be 
wholly based on utility-in-anticipation [14] rather 
than conventional utility-in-us [14].  
 Psychological approaches which mostly 
use HBM to understand people’s health behaviours 
also have several limitations that can limit its use 
in understanding individual’s preventive 
behaviours in the context of obesity. For example 
HBM does not account for other factors that 
influence people’s acceptance or otherwise of a 
health behaviour such as the person’s attitudes, 
habitual behaviours (e.g. addictions), issues of 
social acceptability (hence stigma), cultural factors 
and beliefs, environmental and socio-economic 
factors which may promote or otherwise the 
required action. 
 This review has identified only one study 
[14] which provides some understanding of 
people’s preventive behaviours using a utility 
model. Although the paper is not specific to 
obesity, it can be useful for further empirical 
research into the understanding of people’s 
demand for obesity preventive goods. The paper 
identified 15 variables as the determinants for 
people’s preventive behaviours. It argued that “the 
primary motivating factor in preventive behaviour 
is the anxiety associated with the threat, rather than 
the threat itself.” However, while anxiety can 
result from the awareness of being at risk, there 
can still be many other factors that influence one’s 
anxiety levels in the perspective of weight related 
conditions. For example one’s level of education is 
fundamental to the understanding of the risk. Such 
education is also the impetus for one’s acceptance 
or otherwise of cultural perceptions/beliefs of the 
threat and risks in general. Cultural influences on 
food habits have also been well established [154]. 
In addition, there may also be significant addiction 
elements at play. 
The behavioural economic perspective 
which examines how decisions, under complex 
socio-economic and socio-cultural circumstances 
as well as financial constraints involving trade-
offs, are made by individuals could help to provide 
understanding of people’s preventive behaviours in 
the context of obesity. Since the condition is 
largely behavioural with complex interactions 
between genetic, behavioural, socio-economic, 
cultural and environmental factors, therefore 
behavioural economic, psychological and health 
economic theories will have to be considered 
together to better understand people’s preventive 
behaviours. Any such research into the 
understanding of people’s uptake or otherwise of 
obesity preventive goods should be 
comprehensive. It must be an empirical research 
that captures all or most of the complex variables 
that are at play across the socio-economic and 
socio-cultural divide. 
 
CONCLUSIONS 
 
 Even though the morbidity and mortality 
impacts of obesity are enormous, participations in 
activities considered to be supportive to abnormal 
weight gain preventions are considerably low. It 
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cannot therefore be assumed that there will be a 
demand for all effective preventive goods and 
services. Efforts to increase the demand for obesity 
preventive goods require an understanding of the 
factors which influence individual decisions and 
the personal and practical reasons for resisting 
behaviour change. It is hence imperative for there 
to be further studies into alternative approaches to 
preventive behaviour.  
 The behavioural economic perspective 
could help to increase understanding of the 
preferences of individuals as it examines how 
decisions, under the various often complex socio-
economic and socio-cultural variables as well as 
financial constraints involving trade-offs, are made 
by individuals. Understanding determinants of 
demand for obesity preventive goods can be vital 
in furthering knowledge of how changes in health 
policies will impact on individuals and their 
demand for preventive goods and as well provide a 
platform for effective treatments of weight related 
conditions.  
 Considering the evidences that suggest 
obesity is largely a behavioural issue, and the 
economic restraints on individuals and their 
families, it is surprising that there remains a 
paucity of studies to understand the behaviours of 
individuals from an economic perspective 
regarding demand for obesity preventive goods. It 
will be difficult for one to advance any specific 
reason for this. It is however obvious that 
economic research has instead concentrated on 
studies on the impact of the pandemic on 
healthcare resources and the economy and the 
evaluations of interventions.  
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